Redhill Biopharm Stock Price, News & Analysis

RedHill Biopharma has published new data in the journal GastroHep showing that its drug Talicia achieves high eradication rates for H. pylori infection, irrespective of patient BMI. In a post-hoc analysis of 269 patients, eradication rates reached 88.1% for patients with BMI >30 kg/m² and 90.9% for those with BMI >40 kg/m², compared to active comparators at 62.9% and 31.8% respectively. Talicia is FDA approved as a first-line therapy, offering a promising option for treating H. pylori in overweight and obese populations.

RedHill Biopharma (Nasdaq: RDHL) announced a study published in GastroHep showing that Talicia® effectively eradicates Helicobacter pylori across all body mass index (BMI) groups, including obese patients. The study analyzed data from 269 patients in Phase 3 trials and found eradication rates of approximately 90% for those with BMI over 30 kg/m², significantly outperforming active comparators. Talicia's low resistance rate compared to clarithromycin further underscores its potential as a first-line therapy, especially as obesity is a major risk factor for treatment failure.

RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that Movantik® (naloxegol) has been approved as a preferred and unrestricted brand on a major National Medicare Part D formulary, effective January 1, 2022. This inclusion allows over 10 million Americans access to Movantik for treating opioid-induced constipation. With this approval, Movantik now achieves coverage of 90% of U.S. commercial lives and over 94% of Medicare Part D lives. The company emphasizes the importance of managing constipation associated with opioid use for effective chronic pain management.

RedHill Biopharma announced that its product Movantik (naloxegol) is now preferred and unrestricted on a major National Medicare Part D formulary, effective January 1, 2022. This inclusion expands Movantik's coverage, reaching over 10 million additional Americans and increasing total commercial coverage to 152 million. The drug is the leading treatment for opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

RedHill Biopharma (RDHL) reported its operational highlights and financial results for Q3 2021, achieving record net revenues of $21.6 million. The company saw a 15% increase in new prescriptions for Talicia and 1.1% for Movantik. The gross margin improved from 51% to 57%, and operating loss decreased to $17.4 million from $24.9 million. Notably, opaganib demonstrated a 62% reduction in mortality in a post-hoc analysis of COVID-19 patients. Cash balance stood at $51.5 million as of September 30, 2021, bolstered by strategic investments and a public offering.

RedHill Biopharma (RDHL) is accelerating its COVID-19 clinical programs for opaganib and RHB-107, showcasing their efficacy against the Omicron variant. A Phase 2/3 analysis revealed a 62% mortality reduction in moderately severe patients treated with opaganib. The company reported Q3 2021 net revenues of $21.6 million, with a gross margin increase to 57%. New strategic investments and a $15.5 million public offering bolster its financial position, while Talicia and Movantik continue to see prescription growth, with Talicia's revenue up 117% compared to Q3 2020.

RedHill Biopharma (Nasdaq: RDHL) will announce its Q3 2021 financial results and operational highlights on November 30, 2021. A webcast is scheduled for 8:30 a.m. EST, where key highlights will be presented. The webcast will be available for replay for 30 days. RedHill focuses on gastrointestinal and infectious diseases, promoting drugs like Movantik, Talicia, and Aemcolo. Ongoing clinical developments include RHB-204 for NTM disease and opaganib targeting COVID-19.

On November 23, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) announced the closing of an underwritten public offering of approximately 4.7 million American Depositary Shares (ADSs), raising about $15.5 million in gross proceeds. Each ADS represents ten ordinary shares and was offered by RedHill, which has granted a 30-day option to purchase approximately 0.7 million additional ADSs. The funds will support commercialization activities, clinical development programs, and general corporate purposes.

RedHill Biopharma Ltd. (Nasdaq: RDHL) has priced an underwritten public offering of 4.7 million American Depositary Shares (ADSs) for gross proceeds of $15.5 million. The offering is set to close around November 23, 2021, pending customary conditions. Each ADS represents ten ordinary shares, and the underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase up to an additional 0.7 million ADSs. Funds will support commercialization activities, clinical development, acquisitions, and general corporate purposes.